MX2020006285A - Vacunas contra el cancer dirigidas a survivina y sus usos. - Google Patents
Vacunas contra el cancer dirigidas a survivina y sus usos.Info
- Publication number
- MX2020006285A MX2020006285A MX2020006285A MX2020006285A MX2020006285A MX 2020006285 A MX2020006285 A MX 2020006285A MX 2020006285 A MX2020006285 A MX 2020006285A MX 2020006285 A MX2020006285 A MX 2020006285A MX 2020006285 A MX2020006285 A MX 2020006285A
- Authority
- MX
- Mexico
- Prior art keywords
- survivin
- disclosed
- cancer vaccines
- nucleic acid
- vaccines targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598267P | 2017-12-13 | 2017-12-13 | |
| PCT/US2018/065529 WO2019118766A2 (en) | 2017-12-13 | 2018-12-13 | Cancer vaccines targeting survivin and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006285A true MX2020006285A (es) | 2020-09-17 |
Family
ID=66734396
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006285A MX2020006285A (es) | 2017-12-13 | 2018-12-13 | Vacunas contra el cancer dirigidas a survivina y sus usos. |
| MX2025004799A MX2025004799A (es) | 2017-12-13 | 2020-07-13 | Vacunas contra el cancer dirigidas a survivina y sus usos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025004799A MX2025004799A (es) | 2017-12-13 | 2020-07-13 | Vacunas contra el cancer dirigidas a survivina y sus usos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12064473B2 (https=) |
| EP (1) | EP3723793A4 (https=) |
| JP (3) | JP7385569B2 (https=) |
| KR (2) | KR102648079B1 (https=) |
| CN (1) | CN111479583A (https=) |
| AU (2) | AU2018383664B2 (https=) |
| BR (1) | BR112020011820A2 (https=) |
| CA (1) | CA3083534A1 (https=) |
| MX (2) | MX2020006285A (https=) |
| RU (1) | RU2751253C1 (https=) |
| WO (1) | WO2019118766A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102648079B1 (ko) * | 2017-12-13 | 2024-03-18 | 이노비오 파마수티컬즈, 인크. | 서바이빈을 표적으로 하는 암 백신 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1152402A (en) | 2000-10-04 | 2002-04-15 | Univ Pennsylvania | Highly expressible genes |
| US20110223187A1 (en) * | 2010-02-15 | 2011-09-15 | Vafa Shahabi | Live listeria-based vaccines for central nervous system therapy |
| AU2013243948A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| DK3122375T3 (da) * | 2014-03-28 | 2021-05-25 | Univ Washington Through Its Center For Commercialization | Vacciner mod bryst- og ovariecancer |
| RU2749113C2 (ru) * | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| WO2016179573A1 (en) * | 2015-05-07 | 2016-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Variant survivin vaccine for treatment of cancer |
| US20180305702A1 (en) * | 2015-09-15 | 2018-10-25 | Advaxis, Inc. | Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment |
| KR102648079B1 (ko) * | 2017-12-13 | 2024-03-18 | 이노비오 파마수티컬즈, 인크. | 서바이빈을 표적으로 하는 암 백신 및 이의 용도 |
-
2018
- 2018-12-13 KR KR1020207019758A patent/KR102648079B1/ko active Active
- 2018-12-13 EP EP18889469.5A patent/EP3723793A4/en active Pending
- 2018-12-13 WO PCT/US2018/065529 patent/WO2019118766A2/en not_active Ceased
- 2018-12-13 RU RU2020122872A patent/RU2751253C1/ru active
- 2018-12-13 BR BR112020011820-6A patent/BR112020011820A2/pt unknown
- 2018-12-13 CA CA3083534A patent/CA3083534A1/en active Pending
- 2018-12-13 AU AU2018383664A patent/AU2018383664B2/en active Active
- 2018-12-13 KR KR1020247008261A patent/KR20240038139A/ko active Pending
- 2018-12-13 MX MX2020006285A patent/MX2020006285A/es unknown
- 2018-12-13 CN CN201880080439.6A patent/CN111479583A/zh active Pending
- 2018-12-13 JP JP2020532715A patent/JP7385569B2/ja active Active
- 2018-12-13 US US16/219,520 patent/US12064473B2/en active Active
-
2020
- 2020-07-13 MX MX2025004799A patent/MX2025004799A/es unknown
-
2023
- 2023-08-01 JP JP2023125566A patent/JP7659599B2/ja active Active
-
2024
- 2024-07-08 US US18/765,553 patent/US20240358809A1/en active Pending
- 2024-11-18 AU AU2024264712A patent/AU2024264712A1/en active Pending
-
2025
- 2025-03-28 JP JP2025056239A patent/JP2025092647A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023155245A (ja) | 2023-10-20 |
| KR20240038139A (ko) | 2024-03-22 |
| AU2024264712A1 (en) | 2024-12-05 |
| JP7385569B2 (ja) | 2023-11-22 |
| KR102648079B1 (ko) | 2024-03-18 |
| EP3723793A4 (en) | 2022-01-19 |
| CN111479583A (zh) | 2020-07-31 |
| AU2018383664A1 (en) | 2020-07-16 |
| JP7659599B2 (ja) | 2025-04-09 |
| WO2019118766A3 (en) | 2019-09-19 |
| US20240358809A1 (en) | 2024-10-31 |
| BR112020011820A2 (pt) | 2020-11-17 |
| EP3723793A2 (en) | 2020-10-21 |
| US12064473B2 (en) | 2024-08-20 |
| RU2021117812A (ru) | 2021-07-26 |
| WO2019118766A2 (en) | 2019-06-20 |
| RU2751253C1 (ru) | 2021-07-12 |
| JP2025092647A (ja) | 2025-06-19 |
| KR20200096957A (ko) | 2020-08-14 |
| AU2018383664B2 (en) | 2024-12-05 |
| CA3083534A1 (en) | 2019-06-20 |
| US20190175707A1 (en) | 2019-06-13 |
| MX2025004799A (es) | 2025-05-02 |
| RU2021117812A3 (https=) | 2021-11-08 |
| JP2021506265A (ja) | 2021-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025009055A (es) | Vectores de neoantigeno de alfavirus | |
| IL268836A (en) | Bispecific molecules that bind CD137 and cancer antigens and their uses | |
| PH12019501959A1 (en) | Therapeutic rna | |
| CY1125385T1 (el) | Συστημα πολλαπλων φορεων και χρησεις αυτου | |
| CY1125977T1 (el) | Ενωσεiς που αλληλεπιδρουν με τη γλυκανη και μεθοδοι χρησης | |
| CY1123697T1 (el) | Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη | |
| CY1123274T1 (el) | Αντισωματα εναντι-οχ40 και χρησεις αυτων | |
| CY1122035T1 (el) | Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων | |
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| WO2016106400A3 (en) | Rna interference agents for gst-pi gene modulation | |
| GB2557123A (en) | Modified cells and methods of therapy | |
| MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
| MX2018008051A (es) | Variantes de beta-glucanasa y polinucleotidos que las codifican. | |
| MX2017006652A (es) | Vectores de virus adeno-asociado (aav) dirigidos al sistema nervioso central. | |
| TN2019000015A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| AU2013358947A8 (en) | WT1 vaccine | |
| MX393612B (es) | Vacuna contra viruela para tratamiento del cancer. | |
| SG10201908086SA (en) | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof | |
| MX2024014237A (es) | Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer | |
| MX2020006297A (es) | Variantes de cd19. | |
| MX2020006216A (es) | Vacunas contra el cancer dirigidas a prame y sus usos. | |
| MX2023001540A (es) | Vacunas contra el cancer y metodos de tratamiento que las utilizan. | |
| EP3998341A3 (en) | Adenoviral vectors | |
| EA201891601A1 (ru) | Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей | |
| MX2018005872A (es) | Profarmacos de acido nucleico. |